The Innovation Group | Events company information, Employees & Contact Information

ESMO 2025 – little solace for Roche’s doomed TIGIT | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

The co-inhibitory receptor TIGIT promotes tissue-protective functions in T cells Nature

Dual Immune Checkpoint Blockade Targeting TIGIT and PD 1 Improves Outcomes in Advanced Gastroesophageal Adenocarcinoma Oncodaily

Gilead and Arcus reignite anti-TIGIT interest with Phase II gastric cancer win Clinical Trials Arena

Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers CancerNetwork

Gilead, Arcus keep TIGIT dream alive with 27-month OS data from phase 2 cancer cohort Fierce Biotech

Four Therapies Hanging On in Troubled TIGIT Space BioSpace

Survival data boost prospects for Gilead, Arcus TIGIT drug in gastric cancer FirstWord Pharma

Arcus’s ‘Last TIGIT Standing’ Shows Phase II Survival Benefit Citeline News & Insights

Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets Seeking Alpha

TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies | Cell Death & Disease Nature

5,000 patients later Roche scraps its TIGIT | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Tanja Obradovic Highlights Rilvegostomig’s Unique MoA in AstraZeneca’s TIGIT Program Oncodaily

ESMO 2025 preview – Roche comes clean on TIGIT | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

T-cell responses through a metabolic‒epigenetic mechanism in autoimmune myositis Nature

Another TIGIT bites the dust | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Unlocking the potential of TIGIT in enhancing therapeutic strategies for acute myeloid leukemia through combined azacitidine therapy Nature

BeiGene bows out of TIGIT | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

AACR 2025 preview – Roche's TIGIT postmortem | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

AACR 2025 – a requiem for Roche's TIGIT | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial Nature

Study of Combined TIGIT/PD-1 Blockade Signals Potential Shift in Gastric Cancer Management OncLive

The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble Fierce Biotech

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects BioSpace

Domvanalimab-Based Combo Aims to Leverage Anti-TIGIT Mechanism in Upper GI Cancers OncLive

The dual role of TIGIT in regulatory and effector T cells in chronic liver disease ScienceDirect.com

iTeos, GSK to shelve TIGIT drug after study setback BioPharma Dive

TIGIT antibody with PVR competitive ability enhances cancer immunotherapy and capable of eliciting anti-tumour immune memory Nature

GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs Fierce Biotech

GSK and iTeos drop anti-TIGIT drug following trial failure Pharmaceutical Technology

Another Roche TIGIT disappointment | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

GSK's anti-TIM-3 antibody flunks phase 3 trial as anti-TIGIT failure costs $629M Fierce Biotech

Arcus Biosciences Shows 26.7‑Month Median OS in EDGE‑Gastric | RCUS Stock News Stock Titan

BeiGene abandons ociperlimab over poor phase 3 prospects in latest blow to TIGITs Fierce Biotech

Bristol scores in liver; next up, TIGIT | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

iTeos to shut down following $2bn GSK-partnered TIGIT asset failure Pharmaceutical Technology

A combination of PD-1 and TIGIT immune checkpoint inhibitors elicits a strong anti-tumour response in mesothelioma Journal of Experimental & Clinical Cancer Research

GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of Recent Class Failures BioSpace

iTeos To Close Down After TIGIT Fail BioSpace

Spotlight On: AstraZeneca leads TIGIT charge as another one bites the dust FirstWord Pharma

Promising New Anti‐TIGIT Agents: Stealthy Allies in Cancer Immunotherapy Wiley

Adios, iTeos: Biotech folds weeks after GSK TIGIT termination Fierce Biotech

Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say The American Journal of Managed Care® (AJMC®)

TIGIT expression in extrahepatic cholangiocarcinoma and its impact on CD8 + T cell exhaustion: implications for immunotherapy Nature

BeiGene Scraps TIGIT Candidate After Underwhelming Lung Cancer Data BioSpace

GSK pays $1.2bn for liver drug as it culls TIGIT programme pharmaphorum

iTeos, reeling from TIGIT fail, becomes latest prize for deal-hungry Concentra Fierce Biotech

GSK, iTeos pull the plug on belrestotug as TIGIT stumbles again FirstWord Pharma

More bad vibes kill off Merck’s TIGIT and Lag3 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Tiragolumab and TIGIT: pioneering the next era of cancer immunotherapy Frontiers

GSK and iTeos drop anti-TIGIT drug following trial failure Yahoo Finance

BeiGene bins TIGIT drug after pivotal lung cancer study failure FirstWord Pharma

Inhibition of TIGIT on NK cells improves their cytotoxicity and HIV reservoir eradication potential | mBio ASM Journals

iTeos to shut down operations after TIGIT setback and GSK exit The Pharma Letter

iTeos Therapeutics: TIGIT Falls, And A Zombie Rises? (NASDAQ:ITOS) Seeking Alpha

AACR25: Roche unveils post mortem of anti-TIGIT lung cancer study miss FirstWord Pharma

Anti-TIGIT Shows Promise in Unresectable Liver Cancer MedPage Today

TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation Nature

Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response ScienceDirect.com

Arcus Biosciences Stock May Be The Next To Fail (NYSE:RCUS) Seeking Alpha

Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy Clinical Trials Arena

Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial Nature

BeiGene abandons TIGIT antibody after lung cancer flop pharmaphorum

BeiGene Ends Anti-TIGIT Development In Lung Cancer Citeline News & Insights

Merck drops TIGIT asset and LAG-3 program, discontinuing several phase 3 trials Fierce Biotech

SITC 2024 – Arcus springs a TIGIT surprise | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Roche's TIGIT prospect fails another phase 3 lung cancer test Fierce Biotech

Roche's anti-TIGIT tiragolumab leaves OS hopes unfulfilled in lung cancer study FirstWord Pharma

Roche’s Skyscraper crumbles | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Roche’s TIGIT-targeting drug for cancer fails its biggest test BioPharma Dive

End of the line for MSD's TIGIT, LAG-3 cancer drugs pharmaphorum

A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion ScienceDirect.com

Anti-TIGIT Therapy-Based Treatment Combo Did Not Improve Survival in Extensive-Stage SCLC Cure Today

SITC 2024 preview – duelling TIGIT duds | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

TIGIT, a novel immune checkpoint therapy for melanoma Nature

Where next for TIGIT? | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Astra reveals more about its TIGIT hand | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Arcus, Gilead's TIGIT combo shows survival benefit in scrapped lung cancer study FirstWord Pharma

TIGIT: an immune checkpoint beyond T cells in chronic lymphocytic leukemia Haematologica

Merck joins the TIGIT pivotal failure club | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation ScienceDirect.com

TIGIT blows up in a trial that always looked risky | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Bristol seeks novelty in TIGIT | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ASCO-GI – another surprising TIGIT success? | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

iTeos’s TIGIT enters Arcus territory | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ESMO 2024 – iTeos TIGIT meets its efficacy criteria | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Another twist in the TIGIT saga | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

iTeos’s TIGIT goes pivotal at last | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

ESMO 2024 preview – TIGIT gets its late-breaker | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy ScienceDirect.com

Bristol Myers sends TIGIT drug back to Agenus BioPharma Dive

Structural insights into the unique pH-responsive characteristics of the anti-TIGIT therapeutic antibody Ociperlimab ScienceDirect.com

The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling Cell Communication and Signaling

The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer ScienceDirect.com

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity PNAS

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy Journal of Hematology & Oncology

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses ScienceDirect.com

TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer Frontiers

Novartis retreats from TIGIT, handing $300M candidate back to BeiGene Fierce Biotech

Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial Nature